Evidence map›Paper›PMID 36698396›Full record

ArticleFrontiers in oncology2022

Application of a multispecies probiotic reduces gastro-intestinal discomfort and induces microbial changes after colonoscopy.

Joachim Labenz, Daniela-Patricia Borkenstein, Franz Josef Heil, Ahmed Madisch, Ulrich Tappe, Harald Schmidt, Birgit Terjung, Ingeborg Klymiuk, Angela Horvath, Manfred Gross and 1 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Joachim LabenzDepartment of Internal Medicine, Diakonie Klinikum Jung-Stilling, Siegen, Germany.
Daniela-Patricia BorkensteinDepartment of Internal Medicine, Diakonie Klinikum Jung-Stilling, Siegen, Germany.
Franz Josef HeilPraxis Dr. Heil und Dr. Müller, Andernach, Germany.
Ahmed MadischDepartment of Internal Medicine I, Hospital Clinic Siloah, Hannover, Germany.
Ulrich TappeGastropraxis an der St. Barbara Klinik, Hamm, Germany.
Harald SchmidtPraxis für Innere Medizin und Gastroenterologie Dr. H. Schmidt, Berlin, Germany.
Birgit TerjungGFO Kliniken Bonn, St. Josef-Hospital, Bonn, Germany.
Ingeborg KlymiukDivision of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, Graz, Austria.
Angela HorvathDivision for Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Manfred GrossDepartment of Internal medicine, Internistisches Klinikum München Süd, Munich, Germany.
Vanessa StadlbauerDivision for Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Diakonie Klinikum Jung-Stilling · DEMedical University of Graz · ATAgaplesion Bethanien Krankenhaus · DECenter For Biomarker Research In Medicine · ATMünchen Klinik · DEOrthopädische Praxis · DESt. Marien-Hospital Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Even after decades of research and pharmaceutical development, cancer is still one of the most common causes of death in the western population and the management of cancer will remain a major challenge of medical research. One of the most common types of cancer is colorectal cancer (CRC). Prevention by detection of early-stage precursors is the most reliable method to prevent CRC development. In dependence of age, familial predisposition, and other risk factors the preventative routine screening for CRC by colonoscopy should be performed at least twice in intervals of about ten years. Although colonoscopy is a life-saving clinical examination reducing both incidence and mortality of CRC significantly, it has still a bad reputation in the population as an uncomfortable procedure with unpleasant side effects lasting sometimes over days to weeks. These effects are most likely caused by the bowel preparation before colonoscopy, which is crucial for a successful colonoscopy with high quality. Beside pain, bleeding and other rare but severe complications of colonoscopy, cleaning of the intestinal mucosa alters the gut microbiome significantly and consistently. Abdominal pain, cramps, diarrhea, nausea, bloating, and constipation are common adverse events which can continue to affect patients for days or even weeks after the procedure. In this multicenter, placebo controlled, double blind clinical trial, we investigated the effect of an intervention with a multispecies probiotic formulation for 30 days on the adverse events due to bowel preparation. We show that the treatment of participants with the multispecies probiotic formulation decreases the number of days with constipation significantly, and reduced pain, bloating, diarrhea, and general discomfort. 16S based amplicon analyses reveal recovery of administered probiotic strains from stool samples and differences in alpha diversity dynamics with higher variability in the probiotic group compared to the placebo group. In conclusion, the probiotic ameliorates the side effects after colonoscopy and might be an important supplement to increase acceptance of this life-saving preventative examination. Further, we present here for the first time that probiotic intervention of only 30 days affects alpha diversity parameters in stool samples.

Indexed as

adverse eventscolonizationcolonoscopycolorectal cancerprevention

Identifiers

PMID36698396
PMCPMC9870247
OpenAlexW4313890838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.